Table 1.
Summary of the study characteristic
| Author/year | Country/period of study | Trial name | Study design | Total patients | Gender(M/F) | Median age (years, range) | Primary location | RAS wt/mt/unknown | BRAF wt/mt/unknown |
Primary endpoint | ORR (%) | mPFS (month) | mOS (month) | CLM/R0RR in CLM | mfollow-up (month, range) | MINORS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C Garufi [14]*/2010 | Italy/2006–2008 | POCHER | Pros-, case series | 43 | 27/16 | 61 (33–75) | 34/9a | 30/7/6d | NA | ORR | 79.1% | 14 | 37 | 43/60% | 22 (1–43) | 16 |
| Sougklakos I [16]/2011 | Greece/2007–2010 | - | Pros-, case series | 30 | 16/14 | 64 | NA | 30/0d | NA | ORR | 70% | 11e | NR | 16/57% | 15.1 (NA) | 14 |
| ERIC ASSENAT [17]/2011 | France/2006–2008 | ERBIRINOX | Pros-, case series | 42 | 22/20 | 60 (32–76) | 30/12a | 24/16/2d | NA | CRR | 80.90% | 9.5 | 24.7 | 15/NA | 18.1 (0.4–39.6) | 16 |
| Z Saridaki [18]/2012 | Greece/2007–2010 | - | Pros-, case series | 30 | 14/16 | 64 (36–70) | 22/8a | NA | NA | ORR | 70% | 10.2e | 30.3 | 16/62% | 31 (13–37) | 16 |
| Folprecht, G [19]/2013 | Germany/2014–2018 | CELIM2 | Pros-, cohort | 28 | NA | NA | NA | 28/0/0d | 28/0/0 | ORR | 86% | 15 | 55 | NA | NA | 22 |
| Fornaro, L [20]/2013 | Italy/2010–2011 | TRIP | Pros-, case series | 37 | 21/16 | 63 (33–72) | 26/11a | 37/0/0d | 37/0/0 | ORR | 89% | 11.3 | NR | 12/75% | 17.7 (NA) | 16 |
| Bendell, J. C [21]*/2016 | USA/NA | - | Pros-, case series | 15 | 13/2 | 55 (39–70) | NA | 8/0/7d | NA | ORR | 60% | 13.3 | NR | 15/67% | 15 (NA) | 16 |
| PietrantonioF [22]/2017 | Italy/NA | - | Pros-, case series | 31 | NA | NA | NA | NA | NA | ORR | 87% | 17.8 | 62.5 | 31/84% | 48 (NA) | 14 |
| Cremolini, C [23]/2018 | Italy/2011–2015 | MACBETH | Pros-, multi-center, cohort | 116 | 82/34 | 59.5 (53–67) | 95/21b | 116/0/0 | 116/0/0 | 10m PFR | 71.60% | 10.1 | 33.2 | 52/51.9% | 44 (30.5–52.1) | 24 |
| D Modest [24]/2019 | Germany/NA | VOLFI | RCT, multi-center | 63 | 41/22 | 58 (31–76) | 53/10b | 63/0/0 | 43/7/13 | ORR | 87.3% | 9.7 | 35.7 | NA | 44.2 (NA) | 14 |
| Ogata, T [25]./2019 | Japan/2014–2017 | - | Retro-, cohort | 17 | NA | 60 | 14/3b | 17/0/0 | NA | ORR | 100% | 13.1 | NR | NA | 18.4 (NA) | 21 |
| E Samalin [26]*/2019 | NA | ESTER | Retro-, case series, multi-center | 70 | 43/27 | 58.7 (40.4–74) | 57/13b | 70/0/0 | NA | PFS | 85.70% | 13.3 | 48.5 | 68/79.5% | 49.2 (1.2–135) | 13 |
| Deng, Y [27].*/2020 | China/2014–2019 | FOCULM | Pros-, case series, multi-center | 67 | 58/9 | 52 (28–70) | 66/1b | 67/0/0 | 67/0/0 | Rate of NED | 95.50% | 15.5 | NR | 67/46.3% | 22.6 (NA) | 16 |
| Akihito Tsuji [28]/2021 | Japan/2015–2019 | DEEPER | RCT | 173 | NA | 65 | NA | 173/0/0 | NA | mDpR | 69.10% | 12.7 | 37.6 | NA | NA | 22 |
*All included patients were diagnosed as liver-limited colorectal cancer; acolon/rectum, bleft/right, c14 patients with cetuximab, 3 patients with panitumumab; donly KRAS; etime to progression, TTP; wt, wild-type, mt, mutant-type, ORR objective response rate, mPFS median progression-free survival, mOS median overall survival, CLM colorectal liver-limited metastases, R0RR R0 resection rate, mfollow-up median follow-up, MINORS methodological index for non-randomized studies, pros- prospective study, retro- retrospective study, NA not available, NR not reached, CRR complete response rate, mDpR median depth of response